Q1 Earnings Highlights: Sotera Health Company (NASDAQ:SHC) Vs The Rest Of The Research Tools & Consumables Stocks
This article analyzes the Q1 2026 earnings for Sotera Health Company (NASDAQ:SHC) and compares its performance to other research tools & consumables stocks. It highlights Waters Corporation as the top performer with significant revenue growth, while Revvity showed the weakest performance against analyst estimates. The piece also briefly touches on broader market shifts from AI and crypto anxieties to geopolitical risks influencing investment decisions.
Sotera Health (SHC) amends First Lien Credit Agreement and reprices term loans
Sotera Health Company (SHC) has amended its First Lien Credit Agreement, repricing approximately $1.416 billion in term loans. This amendment reduces the interest rate spread by 0.25%, with the repriced loans now bearing interest at Adjusted Term SOFR plus 2.25%. The loans also include a 1.00% soft call premium for certain repricing transactions within six months and mature on May 30, 2031.
JP Morgan Maintains Sotera Health (SHC) Neutral Recommendation
JP Morgan has reiterated its Neutral recommendation for Sotera Health (SHC). No further details about the reasons for this rating or target price are provided in the given content.
Sotera Health Co stock (US8293551086): litigation overhang eases as business focuses on sterilizatio
Sotera Health Co, trading as SHC on Nasdaq, is navigating ongoing litigation and regulatory scrutiny related to its sterilization operations, while maintaining focus on stable demand for its medical device and pharmaceutical sterilization services. The company emphasizes its role as a critical provider of sterilization, lab testing, and advisory services, relying on long-term contracts and high barriers to entry to ensure recurring revenue. Despite legal challenges, its business model benefits from regulatory-driven demand for product safety and its embedded position within healthcare supply chains.
Warburg Pincus exits Sotera Health (NYSE: SHC) stake; reports zero holdings
Warburg Pincus has filed an amended Schedule 13G/A, signaling a complete exit from its stake in Sotera Health Co. As of May 13, 2026, the various Warburg Pincus entities involved no longer own any shares of Sotera Health Common Stock, reducing their beneficial ownership to 0.00 shares or 0.0% of the class. The filing clarifies the complex organizational structure of the Warburg Pincus Reporting Persons, but does not disclose the mechanics or financial terms of the exit.
GTCR exits stake in Sotera Health Co. (SHC) — reports 0 shares owned
GTCR Reporting Persons have fully exited their stake in Sotera Health Co. (SHC), reporting 0 shares beneficially owned as of May 13, 2026. This information was disclosed in an Amendment No. 7 to their Schedule 13G/A filing. The filing indicates a complete divestment by GTCR Investment XI LLC and its associated funds, though it does not provide details on sale mechanics or proceeds.
GTCR funds sell $193.2m Sotera Health Co stock
GTCR funds have sold their entire holding of 12,735,301 shares in Sotera Health Co (NASDAQ:SHC) for approximately $193.2 million through an underwritten public secondary offering. Following this transaction, GTCR entities no longer own any shares in Sotera Health Co. This sale occurred on May 13, 2026, amidst recent news of Sotera Health's strong Q1 2026 financial results and another secondary offering by affiliates of Warburg Pincus LLC and GTCR LLC.
GTCR funds sell $193.2m Sotera Health Co stock
GTCR investment funds have sold 12,735,301 shares of Sotera Health Co (NASDAQ:SHC) for approximately $193.2 million through an underwritten public secondary offering on May 13, 2026. Following this transaction, the GTCR entities no longer hold any shares in Sotera Health. This sale occurred despite Sotera Health reporting strong Q1 2026 financial results that surpassed expectations.
Sotera Health Co stock (US8293551086): Sponsors exit with 31.8M share sale, agreement terminated
Sotera Health Co's former private equity sponsors, Warburg Pincus and GTCR, have fully exited their investment through a secondary offering of 31.8 million shares at $15.168 per share. This transaction, which closed on May 13, 2026, terminates the Stockholders Agreement and the sponsors' special governance rights. The company, which provides sterilization and lab testing services to the healthcare industry, will now operate with broader public ownership with no ongoing sponsor influence.
Sponsors fully exit Sotera Health (SHC) as 31.8M shares change hands, governance pact ends
Sotera Health's private equity sponsors, Warburg Pincus LLC and GTCR LLC, have fully divested their stake by selling 31.8 million shares at $15.168 each. This sale, which the company will not profit from, marks the end of the sponsors' special corporate governance rights, including their ability to designate board directors. While the sponsors no longer hold common stock, directors they previously appointed may continue to serve until their current terms conclude.
Sotera Health Co - Stockholders' Agreement terminated on May 13, 2026 - SEC filing
Sotera Health Company announced that its Stockholders' Agreement was terminated on May 13, 2026, as per an SEC filing. This news was published on May 13, 2026, at 06:19 pm EDT. The article also provides recent financial updates and company information, including Q1 2026 earnings and executive changes.
[424B7] Sotera Health Co Prospectus Filed Pursuant to Rule 424(b)(7)
Sotera Health Co (SHC) has filed a prospectus supplement for the resale of 31,838,253 shares of common stock by its selling stockholders, Warburg Pincus and GTCR. The company will not receive any proceeds from these sales, which are priced at $15.27 per share. Following this offering, the Sponsors (Warburg Pincus and GTCR) are not expected to hold any remaining shares and will cease to have prior governance rights linked to their ownership.
5 Revealing Analyst Questions From Sotera Health Company’s Q1 Earnings Call
Sotera Health's Q1 2026 earnings showed year-on-year revenue growth due to strong performance in Sterigenics and Nordion, exceeding Wall Street estimates, despite a negative market reaction. Management highlighted improved pricing, customer demand, and effective operations, with March noted as a strong month for volume. Analyst questions focused on Sterigenics' strategy, volume trends, margin outlook, and potential regulatory impacts on capital expenditures.
Press Release: Sotera Health Announces Secondary Offering of Common Stock
Sotera Health has announced a secondary offering of its common stock. The offering is being made by certain selling stockholders, and Sotera Health will not receive any proceeds from the sale of these shares. The company has granted the underwriters a 30-day option to purchase up to an additional number of shares.
Sotera Health: Announces Secondary Offering of Common Stk
This article announces that Sotera Health will undertake a secondary offering of common stock. No further details are available as the article content is empty.
Sotera Health (SHC) Launches Secondary Share Offering of 31.84 M
Sotera Health Co announced a secondary offering of 31.84 million shares of common stock by affiliates of Warburg Pincus and GTCR. The company itself will not sell shares or receive proceeds. SHC's stock has a P/E ratio of 37.63x and a GF Score of 77/100, but recorded significant insider selling worth $610.8 million over the past three months.
Sotera Health’s private equity backers launch secondary offering
Affiliates of Warburg Pincus LLC and GTCR LLC are selling over 31 million shares of Sotera Health common stock in a secondary offering, from which Sotera Health will not receive any proceeds. The offering comes after Sotera Health reported strong Q1 2026 earnings, surpassing expectations, although its stock saw a premarket decline. InvestingPro analysis suggests the stock is currently undervalued.
Sotera Health Announces Secondary Offering of Common Stock
Sotera Health Company (Nasdaq: SHC) has announced a secondary offering of 31,838,253 shares of its common stock. These shares are being sold by affiliates of Warburg Pincus LLC and GTCR LLC, and Sotera Health itself will not be selling any shares or receiving any proceeds from the offering. Goldman Sachs & Co. LLC is acting as the underwriter for the offering.
Warburg, GTCR to sell 31.8M Sotera Health shares in secondary offering
Sotera Health (SHC) announced a secondary offering of 31.8 million common shares, with affiliates of Warburg Pincus and GTCR acting as the sole selling stockholders. Sotera Health will not issue new shares nor receive any proceeds from this offering, though it will cover the offering expenses. This is consistent with previous secondary offerings where existing sponsors sold large blocks of shares, resulting in mixed market reactions.
Number of shareholders of Sotera Health Company – NASDAQ:SHC
This page provides information on the number of shareholders for Sotera Health Company (NASDAQ: SHC). It notes that the specific shareholder value and change percentages are listed for different periods under the company's financial data section on TradingView. The page emphasizes access to market and reference data from various providers like ICE Data Services and FactSet.
Sotera Health Company 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SHC) 2026-05-07
Sotera Health Company (SHC) announced its Q1 2026 earnings, reporting an EPS of $0.18, beating estimates by $0.01. The company's revenue reached $280.05 million, a 10.03% year-over-year increase, surpassing expectations by $9.28 million. This report includes the slide deck presented during their earnings call.
Sotera Health reaffirms 2026 outlook of $1.233B-$1.251B revenue and names Alton Shader CEO effective May 26
Sotera Health has reaffirmed its 2026 financial outlook, projecting revenues between $1.233 billion and $1.251 billion. Additionally, the company announced the appointment of Alton Shader as its new CEO, with his tenure set to begin on May 26.
Sotera Health (Nasdaq:SHC) - Stock Analysis
Sotera Health (SHC) provides sterilization solutions and lab testing for the healthcare industry. The company recently reported strong Q1 2026 results with a return to profitability and reaffirmed its full-year outlook, alongside announcing a CEO transition and dismissal of several ethylene oxide-related lawsuits. Despite positive analyst sentiment and growth forecasts, the stock has lagged the broader market, with legal and regulatory challenges around ethylene oxide remaining a key factor for investors.
Sotera Health (SHC) Margin Improvement To 6.7% Tests Bullish Profitability Narrative
Sotera Health (SHC) recently reported Q1 2026 earnings with a trailing net margin of 6.7%, up from 4% a year ago, on US$1.2 billion in revenue and US$0.27 basic EPS. While earnings grew 75.8% year-over-year, the current margin is below the bullish expectation of 18.3%, and the company faces high P/E valuation, significant debt, and the impact of a US$112.6 million one-off loss. The stock trades below its DCF fair value and analyst targets, prompting a mixed outlook for investors.
Sotera Health taps medical industry veteran Alton Shader as next CEO
Sotera Health has appointed Alton Shader, a medical industry veteran, as its new CEO. Outgoing CEO Michael Petras, who led the company's $1.2 billion IPO, will transition to an executive chairman role, maintaining involvement in investor relations, commercial, and litigation strategies.
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health (SHC)
Three analysts have issued bullish ratings on Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX), and Sotera Health (SHC) within the healthcare sector. JonesTrading maintained a Buy on Editas Medicine with a $3.00 price target, BMO Capital maintained a Buy on Vertex Pharmaceuticals with a $600.00 price target, and William Blair reiterated a Buy on Sotera Health with a $15.00 price target, indicating optimism across these companies.
Wolfe Research lowers Sotera Health stock price target to $19 on valuation
Wolfe Research has lowered its price target for Sotera Health (NASDAQ:SHC) to $19 from $20, while maintaining an Outperform rating. This adjustment comes after the company reported clean first-quarter 2026 results that surpassed Street expectations, with sterilization volumes performing better than anticipated. Despite strong financial performance and a favorable CEO transition, the stock saw a decline in premarket trading.
Sotera Health Signals Steady Growth In Earnings Call
Sotera Health reported strong Q1 2026 results, with double-digit revenue growth and expanding margins, driven by broad-based demand and effective operating discipline. Despite some challenges in Nelson Labs and ongoing regulatory uncertainties, the company affirmed its full-year guidance, bolstered by legal wins and a solid financial position. Leadership changes are also underway to support future growth phases.
Sotera Health (SHC) Q1 2026 lifts profit with 10% revenue growth
Sotera Health (SHC) reported a strong first quarter for 2026, with net revenues increasing by 10% to $280.0 million compared to the previous year. The company achieved a net income of $26.6 million, a significant rebound from a net loss of $13.3 million in Q1 2025, largely due to the absence of the Illinois ethylene oxide litigation settlement that impacted the previous year. Despite ongoing litigation and a high leverage ratio, Sotera Health saw growth driven by pricing gains and higher volumes across its Sterigenics and Nordion segments.
Sotera Health Beat Q1 Estimates And Picked A New CEO
Sotera Health, a medical device sterilization company, surpassed Wall Street's first-quarter sales and profit forecasts and reaffirmed its full-year guidance. The company also announced that Alton Shader will replace Michael Petras Jr. as CEO, with Petras transitioning to executive chairman. This leadership change is intended to maintain strategic consistency while enhancing day-to-day execution, reassuring investors in the stable healthcare supply chain sector.
Sotera Health names new CEO in planned leadership transition
Sotera Health has announced a planned leadership transition, naming a new CEO. The change is part of the company's strategic initiatives for future growth and direction. Further details regarding the outgoing and incoming CEOs were not provided in this snippet.
Sotera Health Company’s (NASDAQ:SHC) Q1 CY2026: Beats On Revenue, Stock Soars
Sotera Health Company (NASDAQ:SHC) reported strong Q1 CY2026 results, exceeding Wall Street's revenue expectations with a 10% year-on-year increase to $280 million. The company's non-GAAP profit was in line with estimates, and it reaffirmed its full-year revenue and adjusted EPS guidance. Following the positive results, the stock traded up 7.2% to $16.50, indicating a solid start to the year driven by healthy organic revenue growth and margin expansion.
Sotera Health announces a new CEO
Sotera Health Co. in Broadview Heights has announced Alton Shader as its new CEO. The news was reported by Crain's Cleveland Business, with the article authored by Elizabeth Schanz and published on May 5, 2026, at 12:20 PM EDT.
Sotera Health (NASDAQ: SHC) posts Q1 growth and plans CEO change
Sotera Health (SHC) announced strong Q1 2026 financial results, with net revenues increasing 10% to $280 million and adjusted EPS up 29% to $0.18. The company reaffirmed its full-year 2026 outlook and revealed a leadership transition, appointing Alton Shader as the new CEO effective May 26, 2026, while current CEO Michael B. Petras, Jr. will become Executive Chairman. This change includes a significant compensation package for Shader and continued involvement for Petras in an executive role.
Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Sotera Health reported strong first-quarter 2026 results with a 10.0% increase in net revenues and net income of $27 million, a significant improvement from a net loss in Q1 2025. The company reaffirmed its full-year 2026 outlook, projecting 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth on a constant currency basis. Growth was primarily driven by Sterigenics and Nordion, while Nelson Labs performed as expected, and two new independent directors joined the Board.
Sotera Health Company (SHC) Surpasses Q1 Earnings and Revenue Estimates
Sotera Health Company (SHC) reported Q1 earnings of $0.18 per share, exceeding the Zacks Consensus Estimate of $0.17, and revenues of $280.05 million, surpassing the estimate by 2.97%. The company has consistently beaten EPS and revenue estimates over the last four quarters. Despite this strong performance, SHC shares have underperformed the S&P 500 year-to-date, and currently hold a Zacks Rank #3 (Hold).
Sotera Health Announces Leadership Transition
Sotera Health has announced a leadership transition, appointing Alton Shader as the new CEO, effective May 26, 2026. Shader, previously CEO of Viant Medical, will also join the Board of Directors. Current Chairman and CEO Michael B. Petras, Jr. will transition to Executive Chairman, continuing to be involved in investor relations, commercial, and litigation strategy.
Sotera Health Announces Leadership Transition
Sotera Health announced a planned leadership transition, with Alton Shader appointed as the new CEO, effective May 26, 2026. Current Chairman and CEO Michael B. Petras, Jr. will transition to Executive Chairman, remaining actively involved in crucial company aspects. Shader, previously CEO of Viant Medical, brings extensive medical industry experience and a track record of growth.
Sotera Health faces earnings test as legal overhang eases
Sotera Health will report its first-quarter results, with analysts expecting 17 cents per share on revenue of $270.8 million, despite a sequential decline attributed to seasonal patterns. Investors are watching the ethylene oxide litigation, regulatory developments, and core business performance across its three operating segments. The company's future hinges on demonstrating that reduced legal risks translate into sustained earnings power.
Sotera Health Company Earnings: What To Look For From SHC
Sotera Health Company (SHC) is set to report earnings this Tuesday before market open. The company beat revenue expectations last quarter and analysts anticipate 6.2% year-on-year revenue growth for the upcoming report. Peers like Avantor and Thermo Fisher have also reported, with Avantor seeing flat revenue but beating expectations and Thermo Fisher showing 6.2% revenue growth.
Sotera Health Company (NASDAQ:SHC) Given Consensus Rating of "Moderate Buy" by Analysts
Analysts have assigned Sotera Health Company (NASDAQ:SHC) a consensus "Moderate Buy" rating, with an average 12-month price target of $20.14. This implies an upside from its current share price of approximately $15.81. The company recently beat quarterly earnings estimates and set optimistic FY2026 guidance, while institutional investors hold over 91% of the stock despite a significant insider sale.
SHC Price Today: Sotera Health Company Stock Price, Quote & Chart | MEXC
This article provides a detailed overview of Sotera Health Company (SHC) stock, including its current price, market data, and recent performance. As of April 28, 2026, SHC is trading at $15.51, reflecting a 1.61% decrease from its previous close, but showing strong performance over the last year with a 37.73% price change. The company specializes in sterilization, analytical lab testing, and advisory services for medical, pharmaceutical, and food products.
3 Healthcare Stocks That Fall Short
This article identifies three healthcare stocks—Sotera Health (SHC), Acadia Healthcare (ACHC), and Bruker (BRKR)—that are currently underperforming and may not be good investment choices. The author highlights concerns such as slow revenue growth, declining profitability, and increased capital intensity for these companies. Each stock's financial metrics and market cap are provided to support the recommendation to avoid them.
Before markets open May 5, Sotera Health will post Q1 results
Sotera Health (SHC) is scheduled to release its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026, for the period ending March 31, 2026. The company will also host a conference call at 9:00 a.m. EDT on the same day to discuss its operating and financial performance. A live webcast and accompanying materials will be available via its investor relations website, with a replay accessible later that day.
Sotera Health Announces First-Quarter 2026 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) has announced that it will release its financial results for the first-quarter ended March 31, 2026, before the market opens on Tuesday, May 5, 2026. Management will host a conference call at 9:00 a.m. EDT on the same day to discuss the results. A live webcast and accompanying materials will be available on the company's Investor Relations website.
Sotera Health Announces First-Quarter 2026 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) announced its plan to release first-quarter 2026 financial results on Tuesday, May 5, 2026, before market open. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the results. A live webcast and accompanying materials will be available via the Investor Relations section of the Company's website.
Sotera Health Announces First-Quarter 2026 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) announced its plan to release first-quarter 2026 financial results on Tuesday, May 5, 2026, before market open. Management will host a conference call at 9:00 a.m. EDT to discuss operating and financial results, with a live webcast available on the Company's Investor Relations website. A replay of the webcast will also be available later that day.
Insiders At Sotera Health Sold US$14m In Stock, Alluding To Potential Weakness
Insiders at Sotera Health have sold US$14 million worth of stock over the past year, with no insider purchases recorded. This significant selling activity, particularly by the CEO and other executives, suggests that some insiders believe the stock price might be overvalued or that future performance could be weaker. While insider selling shouldn't be the sole factor in investment decisions, it can signal a lack of confidence and warrants further investigation into the company's fundamentals.
Barclays Maintains Sotera Health Company(SHC.US) With Buy Rating, Cuts Target Price to $18
Barclays has reiterated its Buy rating for Sotera Health Company (SHC.US) but has lowered its target price to $18 from the previous $20. This adjustment reflects an updated valuation while maintaining a positive outlook on the company's stock.
Sotera Health (NASDAQ:SHC) Downgraded to Buy Rating by Wall Street Zen
Sotera Health (NASDAQ:SHC) was downgraded by Wall Street Zen from a "strong-buy" to a "buy" rating, though the consensus remains a "Moderate Buy" with a $20.43 average target. Despite the downgrade, Sotera Health exceeded Q4 earnings and revenue estimates and raised its FY2026 EPS guidance. Insider transactions showed GTCR Investment XI LLC selling 10 million shares, reducing its ownership by nearly 44%, while institutional investors increased their positions.
